Intervacc AB Company Description

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden.

The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses which is in commercial stage; INV274, antigens for a vaccine against Strep.

suis infectionfor the treatment of weaned piglets which is in development stage; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows which is in development stage.

It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep.

The company was incorporated in 1983 and is based in Hägersten, Sweden.

Intervacc AB (publ)

Country	Sweden
Founded	1983
Industry	Biotechnology
Sector	Healthcare
Employees	15
CEO	Jonas Sohlman

Contact Details

Address: Västertorpsvägen 135 Hägersten, 129 44 Sweden
Phone	46 8 12 01 06 00
Website	intervacc.se

Stock Details

Ticker Symbol	IVACC
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0009607252
SIC Code	2836

Key Executives

Name	Position
Jonas Sohlman	Chief Executive Officer
Jan Persson	Chief Financial Officer
Patrik Hellberg	Chief Investment Officer
Dr. Andrew Waller	Chief Scientific Officer